TY - JOUR
T1 - Comparative effects of BCL-2 inhibition in canine and human breast cancer in vitro models-a review
AU - Raduly, Lajos
AU - Gulei, Diana
AU - Jurj, Anca
AU - Moldovan, Cristian
AU - Balint, Emilia
AU - Marcus, Ioan
AU - Sarpataki, Orsolya
AU - Korban, Schuyler S.
AU - Berindan-Neagoe, Ioana
N1 - Funding Information:
*This work was supported by Project PNCDI III 2015-2020 entitled “Increasing the performance of scientific research and technology transfer in translational medicine through the formation of a new generation of young researchers” – ECHITAS, Research grant No. 128/2014; PN-II-PT-PCCA-2013-4-2166 “New strategies for improving life quality and survival in cancer patients: molecular and clinical studies of the tumor genome in deuterium-depleted water treatment augmentation - GenCanD”, project PN-III-P1-1.2-PCCDI-2017-0782, entitled “Advanced innovative approaches for predictive regenerative medicine”-REGMED., as well as Raduly Lajos-Zsolt won a scholarship from the European Social Found, Human Capital Operational Programme 2014-2021, project no. POCU/380/6/13/125171-ACAMED. **Corresponding authors: ioananeagoe29@gmail.com, ioana.neagoe@umfcluj.ro
Publisher Copyright:
© 2022, Institute of Genetics and Animal Biotechnology of the Polish Academy of Sciences. All rights reserved.
PY - 2022
Y1 - 2022
N2 - Breast cancer is among the leading malignant pathologies in terms of incidence and mortality rates; therefore, rapid development of effective drug treatments, particularly for triple negative breast cancer (TNBC), is of critical importance. One promising approach to speed up the process of drug discovery capitalizes on repositioning of specific therapeutic molecules used for malignancies that have similar altered molecular profiles. In this study, ABT-199, a small molecule that elicits selective inhibition of Bcl-2 and effective against chronic lymphocytic leukemia, is repositioned for treating TNBC using both human and canine breast cancer cell lines. It is observed that ABT-199 elicits similar inhibitory effects, including apoptosis, cell cycle, and migration, on both human and canine breast cancer cells.
AB - Breast cancer is among the leading malignant pathologies in terms of incidence and mortality rates; therefore, rapid development of effective drug treatments, particularly for triple negative breast cancer (TNBC), is of critical importance. One promising approach to speed up the process of drug discovery capitalizes on repositioning of specific therapeutic molecules used for malignancies that have similar altered molecular profiles. In this study, ABT-199, a small molecule that elicits selective inhibition of Bcl-2 and effective against chronic lymphocytic leukemia, is repositioned for treating TNBC using both human and canine breast cancer cell lines. It is observed that ABT-199 elicits similar inhibitory effects, including apoptosis, cell cycle, and migration, on both human and canine breast cancer cells.
KW - breast cancer
KW - canine models
KW - comparative oncology
KW - mammalian cancer model
UR - http://www.scopus.com/inward/record.url?scp=85133711880&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85133711880&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:85133711880
SN - 0860-4037
VL - 40
SP - 5
EP - 22
JO - Animal Science Papers and Reports
JF - Animal Science Papers and Reports
IS - 1
ER -